Article Details
Retrieved on: 2021-06-14 00:11:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Naratuximab (Debio 1562), a CD37-targeting antibody, showed activity in B-NHL in preclinical models when combined with rituximab. CD37 is a ...
Article found on: www.cancertherapyadvisor.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here